Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00340353 · ClinicalTrials.gov registry record
Collection of Alveolar Soft Part Sarcoma and Blood Specimens for Research
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 99,999
- Enrollment target
NCT00340353: Completed study, sponsored by National Cancer Institute (NCI).
NCT00340353 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 99,999 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00340353 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 99,999 participants
- Enrollment target
Study Summary
Background: Alveolar soft part sarcoma (ASPS) is a rare tumor. ASPS is resistant to chemotherapy and radiation. ASPS is characterized by slow growth. Currently no in vitro or in vivo models of ASPS exist for use in experimental therapeutic studies or biological investigations. Primary Objectives: Acquisition of blood and tissue from patients with ASPS. Acquisition of blood from healthy controls for comparison with blood from patients with ASPS. These control samples will be obtained from study NCI at Frederick Protocol OH99-C-N046. Eligibility: Subjects of any age with a diagnosis of primary or metastatic alveolar soft part sarcoma who are undergoing medically indicated surgery for their disease. Design: Patients with Alveolar Soft Part Sarcoma (ASPS) will be eligible for this study. Biopsy tissue will be obtained as an additional sample at the time of a medically indicated procedure. Blood sample may be collected at initial visit and follow-up visits. Specific risks will be described in a separate consent to be obtained at the time of the biopsy. Tumor samples and blood samples will be processed and/or stored for use in research efforts in the laboratory of Dr. David Vistica, National Cancer Institute, Frederick, MD. Additionally, blood samples will be obtained from healthy volunteers for comparison to patients with ASPS. These control samples will be obtained from the National Cancer Institute at Frederick Protocol OH99-C-N046.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99,999 participants |
| Start Date | 2005-04-07 |
| Est. Completion | 2012-04-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00340353
The ClinicalTrials.gov registry entry for NCT00340353 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 99,999 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00340353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00340353 about?
NCT00340353 is a clinical study titled "Collection of Alveolar Soft Part Sarcoma and Blood Specimens for Research". Background: Alveolar soft part sarcoma (ASPS) is a rare tumor. ASPS is resistant to chemotherapy and radiation. ASPS is characterized by slow growth. Currently no in vitro or in vivo models of ASPS exist for use in experimental therapeutic studies or biological investigations. Primary Objective...
What is the current status of trial NCT00340353?
This trial is currently completed. The enrollment target is 99,999 participants. The study started on 2005-04-07. Estimated completion is 2012-04-12.
Who is sponsoring clinical trial NCT00340353?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.